Lumos Pharma Stock Technical Analysis
| LUMO Stock | USD 4.30 0.02 0.46% |
As of the 1st of December, Lumos Pharma secures the Downside Deviation of 3.08, risk adjusted performance of 0.0409, and Mean Deviation of 2.29. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lumos Pharma, as well as the relationship between them.
Lumos Pharma Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Lumos, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to LumosLumos |
Lumos Pharma Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 20.2 | Buy | 3 | Odds |
Most Lumos analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lumos stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lumos Pharma, talking to its executives and customers, or listening to Lumos conference calls.
Lumos Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Lumos Pharma Technical Analysis
The output start index for this execution was ten with a total number of output elements of fifty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Lumos Pharma volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Lumos Pharma Trend Analysis
Use this graph to draw trend lines for Lumos Pharma. You can use it to identify possible trend reversals for Lumos Pharma as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Lumos Pharma price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Lumos Pharma Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Lumos Pharma applied against its price change over selected period. The best fit line has a slop of 0.01 , which means Lumos Pharma will continue generating value for investors. It has 122 observation points and a regression sum of squares at 6.71, which is the sum of squared deviations for the predicted Lumos Pharma price change compared to its average price change.About Lumos Pharma Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Lumos Pharma on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Lumos Pharma based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Lumos Pharma price pattern first instead of the macroeconomic environment surrounding Lumos Pharma. By analyzing Lumos Pharma's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Lumos Pharma's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Lumos Pharma specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 (projected) | Dividend Yield | 4.0E-5 | 3.8E-5 | Price To Sales Ratio | 12.63 | 12.0 |
Lumos Pharma December 1, 2024 Technical Indicators
Most technical analysis of Lumos help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Lumos from various momentum indicators to cycle indicators. When you analyze Lumos charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0409 | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.29 | |||
| Semi Deviation | 2.91 | |||
| Downside Deviation | 3.08 | |||
| Coefficient Of Variation | 2299.84 | |||
| Standard Deviation | 3.33 | |||
| Variance | 11.11 | |||
| Information Ratio | 0.0022 | |||
| Jensen Alpha | 0.216 | |||
| Total Risk Alpha | (0.42) | |||
| Sortino Ratio | 0.0024 | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 16.25 | |||
| Value At Risk | (5.19) | |||
| Potential Upside | 5.95 | |||
| Downside Variance | 9.46 | |||
| Semi Variance | 8.47 | |||
| Expected Short fall | (2.59) | |||
| Skewness | 0.5103 | |||
| Kurtosis | 1.32 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.